Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Canaccord Genuity nudges up target price on Gaming Realms

(Sharecast News) - Analysts at Canaccord Genuity raised their target price on 'buy' rated software publisher Gaming Realms from 50.0p to 57.0p on Monday, stating it was "well-placed" for FY25 following "another record year". Canaccord Genuity said Gaming Realms had made further strong progress delivering another record performance in FY24, with strong growth in both revenues and adjusted underlying earnings as growth was once again driven by its core licensing division.

The Canadian bank stated that "considerable financial and operational progress" has been made over the last six years, which has seen Gaming Realms become "a high margin, cash-generating, global licensed content developer", moving from a small adjusted underlying loss of £300,000 in FY19 to deliver over £13.m in FY24.

"The positive start to the year, coupled with further content and market launches planned across the remainder of FY25E, gives us confidence that our forecasts look well underpinned and so we leave headline revenue and profit forecasts unchanged," said Canaccord. "We expect FY25E to show another year of strong progress driven by further game launches and additional partner distribution agreements."

Canaccord also noted that with its cash balance building, along with management's confidence in the strategy and business model, Gaming Realms has launched an initial £6.0m share buyback programme.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.